27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Wearable devices repeatedly measure activity, sleep, and nocturnal physiology, but their value for three-class cognitive screening remains uncertain. 1 key finding →
Participants: 174 Evidence: low
Full summary, score breakdown and related studies → Original source
Participants were aged 60–94 years, with a mean age of 78.5 ± 7.9 years, and 45.7% were women. 5 key findings →
Design: cross-sectional Participants: 70 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Our findings indicate that HFOs likely arise from different neuronal populations and are generated through distinct mechanisms in these two models. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Controlling for baseline differences, treatment of OSA improved delayed recall and may reduce the slope of memory decline in Alzheimer’s disease and vascular dementia. 3 key findings →
Design: cohort study Participants: 86 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Specific disease clusters involving diabetes, oral disease, sensory impairment, and osteoporosis were associated with suspected dementia and neuropsychiatric heterogeneity, supporting integrated multimorbidity-oriented screening and care. 4 key findings →
Participants: 2,597 Evidence: low
Full summary, score breakdown and related studies → Original source
These findings indicate that the cognitive impact of hearing loss depends on structural resources, highlighting the need to integrate sensory health and social context in dementia prevention efforts. 5 key findings →
Participants: 2,397 Evidence: low
Full summary, score breakdown and related studies → Original source
Our findings reveal marked geographic variation in dementia risk factors, highlighting the need for region-specific prevention strategies. 4 key findings →
Participants: 40,000 Evidence: low
Full summary, score breakdown and related studies → Original source
Because deaths without a given condition differ in cause composition from deaths with it, each condition was also compared with deaths carrying another of the studied conditions: the dementia estimate strengthened to 1.050 (1.036–1.065), and cerebrovascular disease reached 1.018 (1.009–1.027), a smaller but statistically robust positive modification. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
In brain, inverse-variance random-effects meta-analysis (DerSimonian–Laird) across six independent postmortem adult-brain GEO cohorts (GSE33000, GSE132903, GSE173955, GSE159699, GSE5281, GSE48350) yielded 458 analyzable panel genes, 167 at Benjamini–Hochberg FDR < 0.05, and 141 high-confidence genes (FDR < 0.05, measured in at least three cohorts, direction-concordant in at least 70% of cohorts, and nominally significant in at least two cohorts). 1 key finding →
Design: meta-analysis Participants: 329 Evidence: high
Full summary, score breakdown and related studies → Original source
Hypertension is associated with lower risk of dementia-related outcomes in aECAD patients. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
CAD was not associated with global or domain-level neurocognitive performance. 5 key findings →
Design: cohort study Participants: 512 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Cognitive staging and everyday function are not interchangeable. 1 key finding →
Design: retrospective cohort Participants: 202,508 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Participants perceived that interpreter involvement could support communication, direct participation, and the interpretability of assessments when it was timely, appropriately prepared, and aligned with clinical roles. 1 key finding →
Design: cross-sectional Participants: 64 Evidence: low
Full summary, score breakdown and related studies → Original source
These findings indicate that cognitive impairment may mark a population vulnerable to medication complexity rather than independently driving DDI risk, with polypharmacy emerging as the principal modifiable determinant. 4 key findings →
Participants: 101 Evidence: low
Full summary, score breakdown and related studies → Original source
Mean scores were 23.45/30 (78.2%) for general Alzheimer’s disease knowledge and 13.75/18 (76.4%) for BPSD knowledge; the scores were moderately correlated (ρ = .598, p < .001). 3 key findings →
Design: cross-sectional Participants: 196 Evidence: low
Full summary, score breakdown and related studies → Original source
Mean age was 59.6 years, and 57.8% were male. 4 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source
Five core themes and fifteen corresponding sub-themes were extracted from interview transcripts: (1) Structural caregiving context, including family structural constraints, the influence of filial piety culture, and insufficient aged-care supply; (2) Multiple caregiving stressors, covering primary care burden, independent care decision-making pressure, restricted social engagement, and intra-family conflicts; (3) Limited buffering support resources, involving inadequate formal care services, insufficient informal assistance from relatives, and individual psychological coping strategies; (4) Negative caregiving experiences, including persistent physical exhaustion and sustained emotional depletion; (5) Dual perceptions of caregiving outcomes, consisting of emotional gains from kinship bonding, resistance to institutional care, and long-term anxiety about future care arrangements. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Newly diagnosed postoperative depression was associated with increased dementia risk, particularly in patients aged < 65 years, supporting prospective evaluation as a potential marker of long-term cognitive risk. 4 key findings →
Design: cohort study Participants: 424,637 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Depressive and anxiety symptoms were more pronounced among caregivers with longer caregiving duration (p = 0.01; p = 0.001) and those living with the care recipient (p = 0.04; p = 0.02). 4 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source
Late-life depression (LLD) is associated with cognitive impairment, olfactory dysfunction and dementia risk, while brain iron accumulation has been linked to depressive symptoms, cognitive impairment and Alzheimer’s disease progression. 3 key findings →
Participants: 38 Evidence: low
Full summary, score breakdown and related studies → Original source
The study evaluated 1,457 PD patients (1,050 primary; 407 secondary) alongside 2,100 matched non-PD controls. 5 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source
Parkinson disease (PD) was examined in four primary adult-brain GEO cohorts (GSE49036, GSE20141, GSE8397, GSE7621) using a frozen 468-gene redox, metal, xenobiotic, and barrier panel. 1 key finding →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source
Higher UGS coverage was associated with a lower risk of incident AD among older adults in urban South Korea. 4 key findings →
Design: cohort study Participants: 95,822 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →